Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Must have received: proteasome inhibitor

Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).

Must have received: anti-CD38 antibody

Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).

Must have received: immunomodulatory drug

Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).

Cannot have received: adoptive T-cell therapy (CAR T-cell therapy)

Adoptive T-cell therapy (e.g., CAR T-cell therapy) at any time prior to enrollment.

Cannot have received: bispecific antibody

Bispecific antibody, investigational or approved, irrespective of its target, at any time prior to enrollment.

Cannot have received: talquetamab (talquetamab)

Use of talquetamab prior to enrollment.

Cannot have received: BCMA-targeted therapy

Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.

Cannot have received: GPRC5D-targeted therapy

Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant at any time.

Cannot have received: autologous stem cell transplant

Exception: within 2 months of date of enrollment

Autologous stem cell transplant within 2 months of date of enrollment.

Cannot have received: high-dose cytotoxic chemotherapy (DCEP, KD-PACE, D-PACE)

Exception: within 28 days of the enrollment date

High-dose cytotoxic chemotherapy (e.g., DCEP, KD-PACE, D-PACE) within 28 days of the enrollment date.

Cannot have received: cytotoxic chemotherapy (cyclophosphamide)

Exception: within 14 days of the enrollment date

Cytotoxic chemotherapy, such as cyclophosphamide, within 14 days of the enrollment date.

Cannot have received: proteasome inhibitor

Exception: within 7 days of the enrollment date

Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.

Cannot have received: immunomodulatory drug

Exception: within 7 days of the enrollment date

Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.

Cannot have received: anti-CD38 antibody

Exception: within 7 days of the enrollment date

Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.

Cannot have received: BCL2 inhibitor (venetoclax)

Exception: within 7 days of the enrollment date

Treatment with a PI, IMID, anti-CD38 antibody, or venetoclax within 7 days of the enrollment date.

Cannot have received: corticosteroid (dexamethasone)

Exception: cumulative dexamethasone dose of ≥ 100 mg within 14 days of the enrollment date

A cumulative dexamethasone dose of ≥ 100 mg within 14 days of the enrollment date.

Cannot have received: radiation therapy

Exception: within 7 days of the enrollment date

Radiation therapy within 7 days of the enrollment date.